Sunstone announces new investment in neuropsychiatric company Synendos Therapeutics

by | Nov 12, 2020

Copenhagen, 12 November 2020 – Sunstone Life Science Ventures today announces it has invested in a new portfolio company, Synendos Therapeutics AG (“Synendos”), a biopharmaceutical company dedicated to developing novel therapeutics for the treatment of a wide range of central nervous system (CNS) disorders based on modulation of the endocannabinoid pathway. The total financing round is CHF 20 million, and proceeds will be used by Synendos to complete preclinical study and advance lead drug candidate through safety and proof of concept studies.

Press inquiries should be adressed to:

Søren Lemonius

Managing General Partner